Getein Biotech Past Earnings Performance
Past criteria checks 1/6
Getein Biotech has been growing earnings at an average annual rate of 12%, while the Biotechs industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 19.2% per year. Getein Biotech's return on equity is 9.6%, and it has net margins of 17.5%.
Key information
12.0%
Earnings growth rate
12.3%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 19.2% |
| Return on equity | 9.6% |
| Net Margin | 17.5% |
| Next Earnings Update | 30 Apr 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Getein Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 1,446 | 253 | 482 | 232 |
| 30 Jun 23 | 1,552 | 338 | 457 | 231 |
| 31 Mar 23 | 1,635 | 402 | 428 | 227 |
| 31 Dec 22 | 1,822 | 499 | 429 | 223 |
| 30 Sep 22 | 1,857 | 621 | 406 | 196 |
| 30 Jun 22 | 1,775 | 558 | 389 | 185 |
| 31 Mar 22 | 1,696 | 555 | 364 | 178 |
| 31 Dec 21 | 1,402 | 399 | 331 | 163 |
| 30 Sep 21 | 1,283 | 361 | 315 | 152 |
| 30 Jun 21 | 1,344 | 380 | 308 | 144 |
| 31 Mar 21 | 1,251 | 324 | 297 | 133 |
| 31 Dec 20 | 1,123 | 305 | 271 | 119 |
| 30 Sep 20 | 1,101 | 338 | 239 | 119 |
| 30 Jun 20 | 907 | 282 | 227 | 115 |
| 31 Mar 20 | 910 | 298 | 234 | 107 |
| 31 Dec 19 | 968 | 340 | 246 | 105 |
| 30 Sep 19 | 863 | 268 | 252 | 102 |
| 30 Jun 19 | 818 | 273 | 243 | 91 |
| 31 Mar 19 | 749 | 268 | 227 | 87 |
| 31 Dec 18 | 686 | 250 | 211 | 81 |
| 30 Sep 18 | 612 | 236 | 181 | 71 |
| 30 Jun 18 | 587 | 235 | 147 | 85 |
| 31 Mar 18 | 540 | 220 | 144 | 68 |
| 31 Dec 17 | 489 | 194 | 140 | 54 |
| 30 Sep 17 | 451 | 180 | 139 | 33 |
| 30 Jun 17 | 411 | 165 | 158 | 0 |
| 31 Mar 17 | 388 | 153 | 174 | 0 |
| 31 Dec 16 | 369 | 138 | 144 | 0 |
| 31 Dec 14 | 210 | 75 | 92 | 0 |
| 31 Dec 13 | 154 | 66 | 57 | 0 |
Quality Earnings: 603387 has a large one-off gain of CN¥52.7M impacting its last 12 months of financial results to 30th September, 2023.
Growing Profit Margin: 603387's current net profit margins (17.5%) are lower than last year (33.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 603387's earnings have grown by 12% per year over the past 5 years.
Accelerating Growth: 603387's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 603387 had negative earnings growth (-59.3%) over the past year, making it difficult to compare to the Biotechs industry average (-2.6%).
Return on Equity
High ROE: 603387's Return on Equity (9.6%) is considered low.